The Measurement Gap That is Killing Your Pipeline

In the last issue we framed The Prevention Economy. This issue goes deeper for founders and builders, helping you frame why healthcare buyers cannot account for what your product prevents, and what to do about it.

The problem no one names

There is a structural problem in how healthcare systems account for value, and it affects every founder building in prevention, longevity, or proactive health. It is not a funding problem, a clinical evidence problem, or even a product problem. It is an accounting problem.

Healthcare buyers, whether a public health system, an integrated care organisation, a large insurer, or a self-insured corporate employer are built to measure and account for what they do. Consultations delivered. Procedures completed. Admissions managed. Prescriptions issued. The financial architecture of every health system on earth is built around activity. And that architecture shapes what can be justified, funded, and renewed.

When you build in the prevention space, specific markers don't happen. A patient does not deteriorate. An admission does not occur. An emergency does not materialise. The outcome of a successful prevention intervention is, by definition, an absence. And absences do not appear on balance sheets.

The invisible saving

Let me be specific about what this means in practice. Say your product prevents 200 emergency admissions over the course of a year. Those 200 admissions generate, conservatively, substantial avoided costs - bed days, clinical time, emergency procedures. That saving is real. It is documentable, if you know how to measure it.

But in the standard accounting architecture of most healthcare buyers, there is no method to showing the saving. The budget that would have funded those admissions does not appear as a saving. It simply does not get spent. No line item. No entry. No credit to the budget holder who chose your product.

This is not a failure of intelligence on the part of the buyer. It is a structural feature of how health system finance works. The person championing your product inside the organisation; the clinical lead, the innovation director, the programme manager who believes in what you have built, is trying to justify a procurement decision using financial language that the system was never designed to produce.

This is the single most consistent reason I see healthtech procurement stall. Not product quality. Not clinical evidence. Not price. A measurement structure that systematically cannot receive the value your product generates.

This is not a public sector problem

This pattern is not limited to public health systems, and it is not specific to any single country. The same structural issue affects large self-insured employers managing workforce health costs in separate budget lines. It affects European health insurers whose claims accounting does not separate what was prevented from what was treated. It affects integrated care organisations whose value-based contracts were designed to reward outcomes but have not yet produced the data infrastructure to measure them cleanly. It affects private hospital groups running occupational health programmes with no mechanism to attribute productivity improvements to specific interventions.

The pattern is the same everywhere: the buyer experiences the cost of illness in their budget, but has no financial mechanism to account for the value of its absence. For founders, this creates a precise commercial problem. You are selling a value proposition that your buyer's financial system was not built to receive.

Understanding this is not a reason to despair. It is a reason to build your commercial case differently.

Three things to do right now

These are not theoretical fixes. They are the specific interventions that I see make the difference between a deal that closes and one that stalls indefinitely.

1. Before your pilot starts, agree the metrics that matter to the budget holder, not just the clinical lead. Ask explicitly: what does the board use to evaluate this category of spend? What is in the CFO's quarterly review? What does a successful renewal look like in your reporting language? Design your success measurement framework around those questions before the pilot launches, not after. This sounds obvious. In my experience, fewer than one in five founders do it systematically. Most agree outcome metrics with the clinical team, run the pilot against those metrics, and then discover at renewal that the finance team uses an entirely different measurement framework. The clinical case is strong. The commercial case was never built.
2. Build a parallel evidence file, what I call the commercial case, alongside your clinical evidence. The clinical evidence answers: does this work? The commercial case answers: what is the financial exposure if this does not happen, and what does the value look like in the language my buyer reports upwards? These are different documents, written for different audiences, with different evidential standards. Both are necessary.
3. Map the decision tree before you reach heads of terms. In most procurement processes, the person championing your product and the person who controls the budget are not the same person. Understand not just who loves your product, but who has the authority to fund it, and what question they need answered before they will.

The reframe that changes the conversation

The question is not: how do I prove my product works? The evidence, in most cases, is already strong.

The question is: how do I make my buyer's financial system able to receive the value I am generating?

That requires building the commercial case from inside their language, not yours. It means understanding their budget codes, their reporting cycles, their board approval thresholds. It means speaking to the financial decision-maker's agenda, not just the clinical director's. It means making the invisible saving visible in a form that the institution's accounting architecture can actually hold.

This is harder work than producing a clinical evidence pack. It is also the work that gets contracts signed.

Over the next few weeks, I will share more of the frameworks I use with founders to build this commercial case. If this is the challenge you are navigating right now, I would welcome a conversation.

Sara

─────────────────────────────────────────────

P.S. If you work with a healthtech founder who'd find this useful - forward it. The newsletter is free and always will be.